このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

EndoBreast Study - Assessment of Feasibility, Functional Outcomes, and Sensitivity of the Areola-Nipple Complex in Endoscopic Mastectomy (EndoBreast)

2026年7月18日 更新者:Massimiliano Bortolini

Study Design Prospective, single-center, observational, non-interventional study conducted in routine clinical practice. No investigational treatments or modifications to standard diagnostic, therapeutic, or follow-up procedures are planned. Consecutive eligible patients undergoing endoscopic nipple-sparing mastectomy (NSM) with immediate breast reconstruction will be prospectively enrolled.

Background and Rationale Nipple-sparing mastectomy with immediate reconstruction is an established treatment for selected patients with breast cancer and women undergoing prophylactic mastectomy because of hereditary risk. Preservation of the nipple-areola complex (NAC) improves cosmetic outcomes, body image, and patient satisfaction while maintaining oncological safety. Endoscopic NSM is a minimally invasive alternative that may reduce scarring, surgical trauma, and recovery time while improving aesthetic outcomes without compromising oncological radicality. However, evidence remains limited, particularly in Europe, regarding feasibility, perioperative safety, sensory recovery, quality of life, reconstructive outcomes, and long-term oncological results. This study aims to prospectively collect real-world data from a consecutive cohort treated at a specialized breast center.

Primary Objective To evaluate the feasibility and surgical safety of endoscopic NSM with immediate breast reconstruction in patients undergoing prophylactic or therapeutic mastectomy.

Secondary Objectives To evaluate NAC sensory recovery at 6 and 12 months; assess oncological safety through surgical radicality and follow-up; evaluate quality of life and patient satisfaction using validated questionnaires; describe disease-free survival (DFS), overall survival (OS), reconstructive and aesthetic outcomes; and assess postoperative hospital stay.

Primary Endpoints Overall incidence of early surgical complications; incidence of NAC necrosis, skin flap necrosis, infection, seroma, hematoma, hospital readmission, reoperation, and implant loss; recovery of NAC sensation at 6 and 12 months; and pathological assessment of retroareolar margin status.

Secondary Endpoints BREAST-Q scores; local, regional, and distant recurrence; DFS; OS; and reconstructive/aesthetic outcomes.

Study Population and Sample Size Thirty consecutive adult women undergoing prophylactic or therapeutic NSM with immediate implant-based reconstruction according to multidisciplinary evaluation.

Main Inclusion Criteria Female; age 18-75 years; indication for prophylactic or therapeutic NSM; breast volume suitable for endoscopic surgery; Regnault ptosis ≤ Grade II; eligibility for immediate implant-based reconstruction; WHO/ECOG performance status <3; written informed consent.

Main Exclusion Criteria Inflammatory breast cancer or skin involvement; previous breast cancer surgery or radiotherapy to the affected breast; BMI >35 kg/m²; active smoking; ASA Physical Status >2; pregnancy or breastfeeding; inability to provide informed consent; participation in incompatible interventional clinical trials.

Observed Procedure Endoscopic NSM through a lateral inframammary incision using a combined open/endoscopic dissection. Intraoperative retroareolar frozen section and axillary staging (sentinel lymph node biopsy or axillary dissection) will be performed when indicated. Immediate prepectoral implant-based reconstruction will follow.

Data Collection and Follow-up Clinical, surgical, pathological, perioperative, and follow-up data will be prospectively recorded in a dedicated electronic Case Report Form. Patient-reported outcomes will be assessed using the validated BREAST-Q Reconstruction Module. Assessments will be performed preoperatively, intraoperatively, at 30 and 60 days, 6 months, 12 months, and annually up to 5 years. BREAST-Q will be administered at 6 months, 12 months, and annually thereafter.

Study Duration Enrollment will continue until 30 patients have been recruited. Each participant will be followed for 5 years.

Statistical Analysis This descriptive exploratory study will summarize categorical variables as frequencies and percentages and continuous variables using appropriate descriptive statistics. Long-term oncological outcomes will be reported as observed events, with DFS and OS estimated using Kaplan-Meier analysis when appropriate.

Ethics The study is observational and does not alter routine clinical management. No additional significant risks beyond standard surgical care are anticipated. Written informed consent is mandatory. Personal data will be pseudonymized and processed in accordance with the General Data Protection Regulation (EU 2016/679) and applicable national legislation.

Expected Benefits and Risks The study will provide prospective evidence on the feasibility, safety, functional recovery, quality of life, reconstructive outcomes, and oncological effectiveness of endoscopic NSM.

調査の概要

状態

募集

研究の種類

観察的

入学 (推定)

30

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

サンプリング方法

非確率サンプル

調査対象母集団

Thirty consecutive adult women undergoing prophylactic or therapeutic NSM with immediate implant-based reconstruction according to multidisciplinary evaluation.

説明

Inclusion Criteria:

  • Female; age 18-75 years;
  • indication for prophylactic or therapeutic NSM;
  • breast volume suitable for endoscopic surgery;
  • Regnault ptosis ≤ Grade II;
  • eligibility for immediate implant-based reconstruction;
  • WHO/ECOG performance status <3;
  • written informed consent.

Exclusion Criteria:

  • Inflammatory breast cancer or skin involvement;
  • previous breast cancer surgery or radiotherapy to the affected breast;
  • BMI >35 kg/m²; active smoking; ASA Physical Status >2;
  • pregnancy or breastfeeding;
  • inability to provide informed consent;
  • participation in incompatible interventional clinical trials.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
介入・治療
Breast cancer patients
breast cancer patients recruited for endoscopic mastectomy
Endoscopic NSM through a lateral inframammary incision using a combined open/endoscopic dissection. Intraoperative retroareolar frozen section and axillary staging (sentinel lymph node biopsy or axillary dissection) will be performed when indicated. Immediate prepectoral implant-based reconstruction will follow.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Overall incidence of early surgical complications
時間枠:adverse events in the first 90 days
incidence of NAC necrosis, skin flap necrosis, infection, seroma, hematoma, hospital readmission, reoperation, and implant loss
adverse events in the first 90 days
recovery of NAC sensation
時間枠:6-12 months

NAC sensitivity is assessed at five anatomical points: the four quadrants of the areola and the nipple tip. Two complementary tests are used:

  • Cutaneous pressure threshold - Semmes-Weinstein Monofilaments (SWMs): a standardized set of 5 monofilaments with logarithmic force values of 2.83, 3.61, 4.31, 4.56, and 6.65 is applied perpendicularly to each point until the filament bends. The lightest filament perceived by the patient defines the sensory threshold at that point.
  • Spatial discrimination - Weber Two-Point Discrimination Test (TPD): two-point discrimination is evaluated at the four areolar quadrants using a calibrated aesthesiometer; the minimum distance at which the patient can distinguish two separate points is recorded (mm).
6-12 months
pathological assessment of retroareolar margin status
時間枠:1 month

For histological examination of the retroareolar tissue (intraoperative and/or final), the disc-shaped tissue fragment must be submitted with the surface facing the nipple (the "true margin") marked with a suture tag or a metal clip.

Examination of the retroareolar parenchyma may be performed during surgery as an intraoperative frozen-section examination, or after surgery as a final examination.

The retroareolar fragment, generally single, is measured (maximum diameter and thickness), and the surface facing the nipple must be marked by the pathologist with India ink.

Both the frozen-section and the final histopathological examination are performed using serial sections approximately 5 mm apart, from the nipple-facing surface to the breast-facing surface, on the entire submitted specimen.

For the intraoperative histological examination, an average of 3 frozen-tissue sections are prepared at 200-300 micron intervals, followed by an additi

1 month

二次結果の測定

結果測定
メジャーの説明
時間枠
全生存期間 (OS)
時間枠:5年
5年
無病生存期間 (DFS)
時間枠:5年
5年
Reconstruction Module Pre- and Postoperative Scales BREAST-Q® Version 2.0
時間枠:5 years
Score from 0 to 100, where 0 = the worst outcome and 100 = the best outcome
5 years
local, regional, and distant recurrence
時間枠:5 years
5 years
reconstructive/aesthetic outcomes
時間枠:1 year

Reconstructive outcomes: postoperative complications are classified as minor (Grade I-II : events requiring no intervention or managed with pharmacological treatment only) or major (Grade III-V: events requiring surgical, endoscopic, or radiological re-intervention). The primary reconstructive outcome measure is the proportion of patients experiencing at least one minor complication and at least one major complication at each time point, reported separately.

Aesthetic outcomes and health-related quality of life are assessed using the BREAST-Q Reconstruction Module (version 2.0), a validated patient-reported outcome measure (PROM) specifically developed for breast reconstruction. The following domains are evaluated: satisfaction with breasts, satisfaction with overall outcome, psychosocial well-being, physical well-being (chest), and sexual well-being. Each domain is scored on a scale of 0-100 (higher scores indicating better outcomes), derived using the QScore algorithm.

1 year

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年6月23日

一次修了 (推定)

2031年6月30日

研究の完了 (推定)

2031年6月30日

試験登録日

最初に提出

2026年7月6日

QC基準を満たした最初の提出物

2026年7月18日

最初の投稿 (実際)

2026年7月22日

学習記録の更新

投稿された最後の更新 (実際)

2026年7月22日

QC基準を満たした最後の更新が送信されました

2026年7月18日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • CE163/2026

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する